trial

Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers

NCTId NCT06105151
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Recruiting
Enrollment 82 (estimated)
Sponsored by Vigonvita Life Sciences
Primary completion 2025-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Recruiting
Enrollment
82 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2023-10-27
Primary completion
2025-12
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
VV119(SAD)VV119(FE)

Sponsors

Vigonvita Life SciencesLead Sponsor

Investigators

1
Gang Wang, MDPrincipal Investigator

Sites

1 total
Beijing, China

Facts & assertions

4 sourced
Enrollment
82
Phase
PHASE1
Primary Completion Date
2025-12
Status
RECRUITING
relationships
The graph out of here
drug
VV119(SAD)
drug
VV119(FE)
drug
lead_sponsor
Vigonvita Life Sciences
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Gang Wang, MD
person